[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

de Melo Gagliato et al., 2014 - Google Patents

Targeting multiple pathways in breast cancer

de Melo Gagliato et al., 2014

Document ID
11082979937987697147
Author
de Melo Gagliato D
Gonzalez-Angulo A
Publication year
Publication venue
Breast Cancer Management

External Links

Snippet

Breast cancer (BC) is a highly prevalent disease. Worldwide, it is the most common cancer diagnosed and the leading cause of cancer death in women, making this disease a very important focus of interest and research. There is great heterogeneity in clinical outcomes …
Continue reading at www.tandfonline.com (other versions)

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6883Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Similar Documents

Publication Publication Date Title
Luque-Cabal et al. Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome it
Pietrantonio et al. Biomarkers of primary resistance to trastuzumab in HER2-positive metastatic gastric cancer patients: the AMNESIA case-control study
Choudhury et al. Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations
Sabine et al. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study
Tobin et al. The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer
Osborne et al. Mechanisms of endocrine resistance in breast cancer
Majewski et al. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2–targeted therapies in breast cancer
Moroni et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
Vaz-Luis et al. Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?
Milanezi et al. EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy
Røsland et al. Novel points of attack for targeted cancer therapy
Menyhart et al. A comprehensive outline of trastuzumab resistance biomarkers in HER2 overexpressing breast cancer
Nasrazadani et al. Precision medicine in hormone receptor-positive breast cancer
Montemurro et al. Biomarkers of drugs targeting HER‐family signalling in cancer
DeVita Jr et al. Cancer: Principles & practice of oncology: Annual advances in oncology
Tessari et al. Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients
Pernas et al. Targeting HER2 heterogeneity in early-stage breast cancer
Patel et al. Personalized treatment for advanced colorectal cancer: KRAS and beyond
Triulzi et al. Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge
JP2016535079A (en) Nucleic acid biomarkers and uses thereof
Rickman et al. Analysis of ErbB receptors in pulmonary carcinoid tumors
Zhou et al. Prognostic and therapeutic molecular markers in the clinical management of esophageal cancer
Eng The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development
Clarke et al. Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors
Aftimos et al. Molecular biology of breast cancer